Telix Pharmaceuticals Limited: Telix Joins Thera4Care with TLX400-Tx to Accelerate Translation of Next Generation FAP-Targeting Theranostics
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) has joined the Thera4Care initiative to evaluate its FAP-targeting therapy candidate, TLX400-Tx, with terbium-161. The collaboration aims to accelerate the development of next-generation theranostics for cancer treatment, focusing on ovarian, pancreatic cancers, and sarcomas. Telix will contribute to preclinical and clinical activities, with data expected to inform future development directions.


